 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...75767778798081828384858687» |
- ||| Prolia (denosumab) / Amgen
New trial: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Aug 11, 2015
P=N/A, N=575462, Recruiting, Sponsor: Amgen
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: AfterDmab: Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation (clinicaltrials.gov) - Jul 16, 2015
P4, N=90, Recruiting, Sponsor: 424 General Military Hospital
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (clinicaltrials.gov) - Jul 14, 2015
P3, N=795, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting
- |||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI (clinicaltrials.gov) - Jul 9, 2015
P3, N=150, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Prolia (denosumab) / Amgen
Enrollment closed, Combination therapy, Metastases: Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 9, 2015
P2, N=226, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Trial primary completion date: A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors (clinicaltrials.gov) - Jul 9, 2015
P3, N=477, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Dec 2015
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: Effects of Denosumab Therapy for Japanese (clinicaltrials.gov) - Jul 8, 2015
P=N/A, N=500, Recruiting, Sponsor: Tomidahama Hospital
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Trial primary completion date, Metastases: Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss (clinicaltrials.gov) - Jun 26, 2015
P3, N=760, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Jun 2016
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Survey of XGEVA (clinicaltrials.gov) - Jun 16, 2015
P=N/A, N=420, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Jun 2016 Recruiting --> Completed
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: AOST1321: Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Jun 12, 2015
P2, N=90, Not yet recruiting, Sponsor: Children's Oncology Group
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients (clinicaltrials.gov) - Jun 11, 2015
P4, N=100, Recruiting, Sponsor: Shinshu University
Recruiting --> Completed Trial primary completion date: Sep 2014 --> May 2015
- Prolia (denosumab) / Amgen
Trial primary completion date, IO biomarker: D-Beyond: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=39, Recruiting, Sponsor: Jules Bordet Institute
Trial primary completion date: Sep 2014 --> May 2015 Trial primary completion date: Jan 2015 --> Dec 2016
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date, Metastases: ABCSG-18: Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy (clinicaltrials.gov) - Jun 11, 2015
P3, N=3425, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Oct 2014
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Enrollment change: Estimation of Off-Label Use of XGEVA (clinicaltrials.gov) - May 29, 2015
P=N/A, N=142, Completed, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Oct 2014 Enrolling by invitation --> Completed | N=108 --> 142
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty (clinicaltrials.gov) - May 27, 2015
P2, N=64, Active, not recruiting, Sponsor: Hans Mallmin
Enrolling by invitation --> Completed | N=108 --> 142 Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: TNFSF11 Inhibition and Fertility: a Prospective Study (clinicaltrials.gov) - May 21, 2015
P2, N=15, Recruiting, Sponsor: Martin Blomberg Jensen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: EDRPBLFHR: Longjohn Amgen Study - Effect of Denosumab... (clinicaltrials.gov) - May 14, 2015
P=N/A, N=80, Not yet recruiting, Sponsor: University of Southern California
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis (clinicaltrials.gov) - May 12, 2015
P4, N=40, Completed, Sponsor: Tuen Mun Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index (clinicaltrials.gov) - May 6, 2015
P=N/A, N=90, Recruiting, Sponsor: HealthEast Care System
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: TNFSF11 Inhibition and Fertility: a Prospective Study (clinicaltrials.gov) - Apr 21, 2015
P2, N=15, Not yet recruiting, Sponsor: Martin Blomberg Jensen
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1/2 trial: Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders (clinicaltrials.gov) - Apr 16, 2015
P1/2, N=24, Not yet recruiting, Sponsor: Indiana University
- Prolia (denosumab) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Denosumab in Primary Hyperparathyroidism (clinicaltrials.gov) - Apr 9, 2015
P4, N=8, Completed, Sponsor: John P. Bilezikian
Active, not recruiting --> Completed Recruiting --> Completed | N=28 --> 8 | Trial primary completion date: Jan 2016 --> Oct 2014
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP (clinicaltrials.gov) - Apr 7, 2015
P2b, N=41, Recruiting, Sponsor: Elizabeth Shane
Recruiting --> Completed | N=28 --> 8 | Trial primary completion date: Jan 2016 --> Oct 2014 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Trial initiation date: Denosumab Administration After Spinal Cord Injury (clinicaltrials.gov) - Mar 26, 2015
P2, N=24, Recruiting, Sponsor: James J. Peters Veterans Affairs Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jan 2015
- |||| Prolia (denosumab) / Amgen
Trial completion: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Mar 17, 2015
P4, N=643, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting | Initiation date: Apr 2014 --> Jan 2015 Active, not recruiting --> Completed
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Trial completion, IO biomarker: Effect of Denosumab on Cellular Biomarkers in the Human Breast (clinicaltrials.gov) - Mar 10, 2015
P1, N=82, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: China HVT Safety, PK, PD (clinicaltrials.gov) - Mar 9, 2015
P1, N=64, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Prolia (denosumab) / Amgen
Trial primary completion date, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Mar 7, 2015
P2, N=45, Recruiting, Sponsor: Hope Rugo, MD
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (clinicaltrials.gov) - Mar 5, 2015
P3, N=776, Recruiting, Sponsor: Amgen
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Jun 2015 --> Jun 2017
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Metastases: Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease (clinicaltrials.gov) - Feb 19, 2015
P4, N=0, Withdrawn, Sponsor: Amgen
Trial primary completion date: Jun 2015 --> Jun 2017 N=100 --> 0 | Initiation date: Aug 2014 --> Nov 2014 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Nov 2014
- | Prolia (denosumab) / Amgen, Xofigo (radium Ra-223 dichloride) / Bayer
New P2 trial, Combination therapy, Metastases: Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=36, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Trial initiation date, Trial primary completion date: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Feb 11, 2015
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=100 --> 0 | Initiation date: Aug 2014 --> Nov 2014 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2016 --> Nov 2014 Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Nov 2019 --> Feb 2020
- |||||| Prolia (denosumab) / Amgen
Enrollment open, Trial initiation date, Metastases: SPLENDOUR: Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy (clinicaltrials.gov) - Feb 10, 2015
P3, N=1000, Recruiting, Sponsor: European Thoracic Oncology Platform
Initiation date: Nov 2014 --> Feb 2015 | Trial primary completion date: Nov 2019 --> Feb 2020 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab and Teriparatide Study (DATA-HD and DATA-EX) (clinicaltrials.gov) - Feb 5, 2015
P4, N=70, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015 Not yet recruiting --> Recruiting
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P3 trial: Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI (clinicaltrials.gov) - Feb 2, 2015
P3, N=150, Not yet recruiting, Sponsor: Amgen
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer (clinicaltrials.gov) - Jan 30, 2015
P3, N=129, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | N=400 --> 129 | Trial primary completion date: Dec 2014 --> Jun 2017
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical: PILOTE: Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=750, Not yet recruiting, Sponsor: Amgen
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab (clinicaltrials.gov) - Jan 28, 2015
P2, N=10, Completed, Sponsor: University of Cologne
Enrolling by invitation --> Active, not recruiting | N=400 --> 129 | Trial primary completion date: Dec 2014 --> Jun 2017 Active, not recruiting --> Completed
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Trial primary completion date, IO biomarker: Effect of Denosumab on Cellular Biomarkers in the Human Breast (clinicaltrials.gov) - Jan 26, 2015
P1, N=82, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Jul 2014
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial primary completion date: Observational Study of Denosumab (Prolia (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=1501, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Oct 2014 --> Jul 2014 Trial primary completion date: Nov 2014 --> Aug 2015
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P1/2 trial: The Efficacy of Denosumab in Active Crohn's Disease (clinicaltrials.gov) - Dec 22, 2014
P1/2, N=30, Not yet recruiting, Sponsor: University of Manitoba
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (clinicaltrials.gov) - Dec 10, 2014
P3, N=642, Active, not recruiting, Sponsor: Daiichi Sankyo Inc.
Trial primary completion date: Nov 2014 --> Aug 2015 Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Trial initiation date: SALTIRE II: Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis. (clinicaltrials.gov) - Dec 6, 2014
P2, N=150, Recruiting, Sponsor: University of Edinburgh
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Nov 2014
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: Denosumab for Treating Periprosthetic Osteolysis. (clinicaltrials.gov) - Nov 24, 2014
P2, N=110, Not yet recruiting, Sponsor: Olof Skoldenberg
- Prolia (denosumab) / Amgen
Enrollment open, Metastases: Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid (clinicaltrials.gov) - Nov 24, 2014
P1, N=24, Recruiting, Sponsor: OPKO Ireland Global Holdings Ltd.
Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion: Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product (clinicaltrials.gov) - Nov 14, 2014
P1, N=146, Completed, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment open, Trial initiation date, Trial primary completion date: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Nov 7, 2014
P2, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Withdrawn --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Jul 2019 --> Nov 2019
- Prolia (denosumab) / Amgen
New P1 trial, Metastases: Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid (clinicaltrials.gov) - Oct 24, 2014
P1, N=24, Not yet recruiting, Sponsor: OPKO Ireland Global Holdings Ltd.
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Enrollment change, Trial withdrawal: Denosumab for Breast Cancer With Bone Mets (clinicaltrials.gov) - Oct 23, 2014
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Withdrawn --> Recruiting | Initiation date: Jul 2014 --> Nov 2014 | Trial primary completion date: Jul 2019 --> Nov 2019 N=35 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Denosumab China Phase III Study (clinicaltrials.gov) - Sep 29, 2014
P3, N=444, Active, not recruiting, Sponsor: GlaxoSmithKline
N=35 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting